Trust Signals
Written by the FormBlends Medical Team. Every claim is graded by evidence type. Speculative mechanisms are labeled. No compound is recommended for unsupervised use. This page is for educational and research purposes only and does not constitute medical advice.
Key Takeaways
- Semax, a 7-amino-acid ACTH analogue registered as a drug in Russia, has the strongest human trial base of any research peptide in this category, though no trial exceeds roughly 100 participants.
- Dihexa binds the HGF/MET receptor system with extremely high reported affinity in rodent data and promotes synaptogenesis in animal models, but zero published human trials exist as of 2025.
- Blood-brain barrier penetration is the single most underreported limitation: most subcutaneously injected peptides reach the CNS at negligible concentrations without intranasal or intrathecal delivery.
- Cerebrolysin has the most RCT data for neurodegenerative and post-stroke contexts, including multiple trials in Alzheimer's disease, and is approved in some countries outside the United States.
- No cognitive research peptide has FDA approval for healthy adults; all comparisons to modafinil or approved Alzheimer's drugs favor the approved agents on regulatory evidence and long-term safety data.
What Is the Best Peptide for Brain Function Right Now?
Semax holds the best evidence-to-risk profile among research peptides for brain function, with human trials, a plausible BDNF-linked mechanism, and decades of clinical use in Russia. For neurodegeneration specifically, Cerebrolysin has more RCT data. No peptide in this category beats modafinil on regulatory evidence for healthy wakefulness and cognition.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- Evidence Ledger: How These Peptides Compare
- The Top Peptide Candidates Ranked
- How Do Brain Peptides Actually Work? Mechanism With Numbers
- The Blood-Brain Barrier Problem Most Pages Ignore
- Honest Head-to-Head: Peptides vs Approved Cognitive Agents
- What Most Pages Get Wrong About Cognitive Peptides
- Operational and Label Literacy: Reading a COA, Dosing, Storage
- Which Peptide Is Best for Neurodegeneration vs Healthy Enhancement?
- FAQ
- Sources
Evidence Ledger: How Do These Peptides Compare?
The table below grades the core claims behind each candidate. Evidence type and confidence are explicit. Claims not yet tested in humans are marked accordingly.
| Peptide | Primary Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|---|
| Semax | Improves attention, memory, neuroprotection | Small human RCTs (Russia-registered drug) | Positive | Moderate |
| Cerebrolysin | Slows cognitive decline in Alzheimer's / post-stroke recovery | Multiple RCTs, Cochrane review | Modestly positive | Moderate |
| Selank | Anxiolytic with preserved cognition | Small human trials, animal data | Positive | Low-Moderate |
| Dihexa | Synaptogenesis, cognitive rescue | Rodent studies only | Positive (animals) | Very Low (no human data) |
| BPC-157 | Neuroprotection, dopamine system support | Rodent models | Positive (animals) | Very Low (no human data) |
| NSI-189 | Hippocampal neurogenesis, antidepressant | One Phase II trial (MDD, missed primary endpoint) | Mixed | Low |
| Epithalon | Telomere extension, neuroprotection | Animal and limited human observational data | Unclear | Very Low |
What Are the Top Peptide Candidates and What Does Each One Actually Do?
1. Semax
Semax is a heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from the ACTH(4-10) fragment. It is registered in Russia as a drug for stroke recovery, optic nerve disease, and cognitive deficit states. Mechanism involves upregulation of BDNF and NGF, modulation of dopaminergic and serotonergic neurotransmission, and anti-inflammatory effects on CNS microglia. The key differentiator is that it is almost always administered intranasally, which allows olfactory nerve bypass of the blood-brain barrier. Published Russian clinical trials report improvements in attention tasks and memory consolidation, though trial registrations and full datasets are not consistently available in Western databases, which limits independent replication confidence.
2. Cerebrolysin
Cerebrolysin is a peptide mixture derived from hydrolyzed porcine brain tissue, standardized to contain approximately 25 percent low-molecular-weight peptides including fragments of NGF, BDNF, CNTF, and GDNF. A Cochrane-level systematic review of Cerebrolysin in vascular dementia found some evidence of benefit on global clinical impression and cognitive scales, though effect sizes were modest and heterogeneity was high. For post-stroke motor recovery, a large multicenter RCT (CARS trial) showed improvements in motor function at 90 days compared to placebo. It is approved in Austria, Germany, China, and several other countries. It is not FDA approved.
3. Selank
Selank is a synthetic analogue of the endogenous tetrapeptide tuftsin (Thr-Lys-Pro-Arg) with added stabilizing residues. It modulates GABAergic tone, reduces degradation of enkephalins, and has been shown in animal studies to upregulate BDNF in the hippocampus. Small Russian human trials in generalized anxiety disorder show anxiolytic effects comparable to benzodiazepines, but without the sedation or dependence profile. The cognitive angle is that anxiety itself degrades working memory and executive function; Selank's value may be more about removing a cognitive suppressant than directly enhancing capacity.
4. Dihexa
Dihexa (N-hexanoic acid-Tyr-Ile-His-Pro-Phe) is derived from angiotensin IV and acts at the HGF/MET receptor complex, which governs synaptic plasticity and neuronal survival. In a study by McCoy et al. at Washington State University, Dihexa was reported to be roughly 10 million times more potent than BDNF in a dendritic spine formation assay in rodents. This figure is striking and widely cited, but it was derived from in vitro and rodent models. There are no published Phase I or Phase II human trials. The long-term safety of HGF/MET agonism is a real concern because MET is also a proto-oncogene; sustained activation could theoretically promote cell proliferation in tissues other than neurons.
5. BPC-157
BPC-157 is a 15-amino-acid synthetic peptide derived from a partial sequence of body protection compound found in gastric juice. Its best evidence base is for gut healing and tendon repair. In rodent models of dopamine system disruption (using 6-OHDA lesions), BPC-157 partially reversed dopaminergic deficits. GABAergic pathway modulation has also been proposed. There are no published human trials for any neurological or cognitive endpoint. Extrapolating rodent neuroprotection data to human brain function is a large inferential leap.
6. NSI-189
NSI-189 is a small synthetic compound (not a classical peptide, though often grouped here) that was developed by Neuralstem Inc. to stimulate hippocampal neurogenesis. In rodents it increased hippocampal volume. A Phase II RCT in major depressive disorder published by Fava et al. in 2016 (Molecular Psychiatry) found that while some secondary cognitive endpoints showed improvement, the primary depression endpoint was not statistically met. For healthy cognitive enhancement, there is essentially no controlled human data.
How Do Brain Peptides Actually Work? Mechanism With Specific Numbers
Three core biological targets explain most of this category:
BDNF and neurotrophic signaling. BDNF (brain-derived neurotrophic factor) binds TrkB receptors and activates MAPK/ERK and PI3K/Akt cascades, which promote dendritic branching, synaptic protein synthesis, and long-term potentiation. Semax has been shown in rodent models to increase BDNF mRNA expression in the hippocampus and frontal cortex within hours of intranasal administration. The caveat: BDNF elevation measured in rodent hippocampus after a nasal dose does not confirm equivalent changes in human cortical circuits or that those changes translate to measurable cognitive outcomes on validated tests.
HGF/MET synaptogenesis (Dihexa). The HGF receptor MET, when activated, promotes formation of dendritic spines, the physical substrate of memory storage. McCoy et al. reported that Dihexa induced dendritic spine density increases in hippocampal cell culture at concentrations far below those needed for BDNF to produce the same effect. The oncology concern: MET amplification is found in gastric, lung, and hepatocellular cancers. Long-term systemic MET agonism has never been tested for safety in humans.
GABAergic and enkephalinergic modulation (Selank, BPC-157). Selank is believed to inhibit enkephalin-degrading enzymes, prolonging endogenous opioid peptide activity at delta receptors, which in turn modulates GABAergic inhibitory tone. This differs from benzodiazepines, which directly potentiate GABA-A receptor chloride conductance. The clinical implication is a potentially cleaner anxiolytic effect without receptor downregulation, but this mechanistic differentiation has not been proven to matter in large human trials.
The Blood-Brain Barrier Problem Most Pages Ignore
This is the single most important limitation that commodity pages omit entirely.
The blood-brain barrier is formed by tight-junction endothelial cells lining cerebral capillaries, supported by astrocytic end-feet and pericytes. Molecules larger than roughly 400 to 600 daltons and with significant polarity are effectively excluded from passive transcellular diffusion. Most peptides exceed this threshold or are too hydrophilic.
Semax (molecular weight approximately 813 Da) and Selank (approximately 1000 Da) are routinely administered intranasally because the olfactory epithelium provides a direct axonal transport pathway to olfactory bulb and ultimately limbic and cortical structures, partially circumventing the BBB. This is not 100 percent efficient, but it meaningfully increases CNS bioavailability compared to subcutaneous injection of the same dose.
Dihexa is an exception in this list: it was specifically engineered to be lipophilic and orally bioavailable, and it does demonstrate CNS penetration in rodent studies after oral or peripheral dosing. This is rare for a peptide of its class.
BPC-157 administered subcutaneously or intraperitoneally in rodents shows systemic anti-inflammatory and healing effects. Whether meaningful concentrations reach CNS tissue in humans after subcutaneous injection is not established. Anyone claiming that subcutaneous BPC-157 protects human neurons based on rodent data is making an inferential leap the evidence does not support.
Cerebrolysin is administered intravenously in clinical trials, which allows direct CNS access for its smallest peptide fragments while larger components may still face BBB restriction.
Honest Head-to-Head: Peptides vs Approved Cognitive Agents
Credibility requires conceding where peptides lose. The table below is honest about those comparisons.
| Agent | Regulatory Status | Human RCT Evidence | Mechanism Specificity | Long-Term Safety Data | Practical Verdict |
|---|---|---|---|---|---|
| Modafinil | FDA-approved (narcolepsy, shift work) | Multiple large RCTs | DAT/orexin, well-characterized | Strong, decades of use | Wins on evidence and safety |
| Donepezil (AChEI) | FDA-approved (Alzheimer's) | Multiple large RCTs | AChE inhibition, clear | Strong for indicated population | Wins for neurodegeneration |
| Cerebrolysin | Approved in some EU/Asian countries, not FDA | Multiple RCTs, Cochrane data | Neurotrophic peptide mix | Moderate, IV administration risk | Competitive for neurodegeneration, limited by route |
| Semax | Registered drug in Russia, research compound elsewhere | Small human trials | BDNF/NGF upregulation | Limited Western data | Promising; loses on trial scale and regulatory standing |
| Selank | Research compound outside Russia | Small human trials | GABAergic/enkephalin | Limited | Narrow advantage in anxiolytic-cognitive overlap use case |
| Dihexa | Research compound only | None in humans | HGF/MET (oncology concern) | Unknown | Loses badly on safety profile and evidence until trials exist |
| Racetams (e.g., piracetam) | Approved in some EU countries, not FDA | Moderate RCT base | AMPA receptor modulation | Decades of use, favorable | Beats most research peptides on safety history |
What Most Pages Get Wrong About the Best Peptide for Brain Function
Conflating rodent data with human efficacy. The majority of blogs cite Dihexa's rodent synaptogenesis data or BPC-157's dopamine rescue in 6-OHDA rat models as if these findings establish human cognitive benefit. They establish a hypothesis worth testing, nothing more. The history of neuroprotective drugs is littered with compounds that looked extraordinary in rodents and failed or caused harm in humans.
Ignoring route of administration entirely. A page that says "take Semax for brain function" without specifying intranasal delivery is omitting the pharmacologically critical detail. Subcutaneous Semax does not reliably reach the CNS at effective concentrations based on available data. The same dose, same peptide, different route yields a fundamentally different pharmacokinetic outcome.
Presenting purity claims without COA literacy. Vendor marketing routinely states "99 percent pure" without clarifying what the 1 percent residual is. Endotoxin contamination at even trace levels can trigger neuroinflammation, which directly opposes every claimed cognitive benefit. A purity HPLC trace is not the same as an endotoxin assay.
Underreporting the oncology risk of MET agonism. Dihexa receives enthusiastic coverage on nootropic forums. The MET proto-oncogene concern is rarely mentioned. This is not a reason to dismiss the compound, but it is a reason to treat it as genuinely experimental rather than a smart supplement.
Treating all "neuroprotective" claims as equivalent. Neuroprotection in a rodent model of acute traumatic injury and cognitive enhancement in a healthy human are entirely different claims requiring entirely different evidence types. Most peptide pages merge them without distinction.
Operational and Label Literacy: How to Evaluate a Product, COA, and Dosing
Reading a COA for Cognitive Peptides
Minimum requirements for a credible COA on any peptide intended for intranasal or injectable use near neural tissue:
- HPLC purity above 98 percent, with the actual chromatogram trace, not just a reported number.
- Mass spectrometry (ESI-MS or MALDI) confirming the correct molecular weight, ruling out truncated or scrambled sequences.
- Residual solvent testing by gas chromatography, particularly for acetonitrile and TFA commonly used in synthesis.
- Endotoxin (LAL) testing below 1 EU per mg for any intranasally or parenterally administered compound. This is non-negotiable.
- Lot number and date, so you can cross-reference if a batch is recalled.
Reconstitution and Storage
Lyophilized peptide vials should be stored below minus 20 degrees Celsius in a dark environment. The reason: peptide bonds are susceptible to acid or base hydrolysis, and oxidation of methionine and cysteine residues occurs at room temperature over days to weeks. Semax and Selank both contain residues vulnerable to oxidative degradation. Reconstitute with bacteriostatic water (0.9 percent benzyl alcohol as preservative) for multi-dose vials, or sterile water for single-dose use. Avoid vortex mixing, which generates shear forces and air-water interfaces that promote aggregation and fibril formation. Gentle swirling or rotation is appropriate.
Once reconstituted and refrigerated at 2 to 8 degrees Celsius, most research peptides in this class maintain acceptable stability for roughly 4 to 8 weeks. Specific stability data for Semax in aqueous solution is limited in the published literature; conservative practitioners treat 4 weeks as the working window. Intranasal preparations need sterile, preservative-free diluents to avoid ciliostatic effects from benzyl alcohol on olfactory epithelium.
Dosing Reference
| Peptide | Common Research Protocol Dose | Route | Frequency | Caveat |
|---|---|---|---|---|
| Semax | 200 to 600 mcg per day | Intranasal | Once or twice daily | Russian trial dosing; no Western RCT dose-finding |
| Selank | 250 to 500 mcg per day | Intranasal | Once or twice daily | Based on Russian clinical data only |
| Cerebrolysin | 10 to 30 mL per infusion | IV infusion | Daily for 10 to 20 days per cycle | Requires clinical setting; IV only in trials |
| Dihexa | No established human dose | Oral or topical in animal studies | Unknown | No human trials; any dose is extrapolated |
| BPC-157 | 200 to 500 mcg per day (animal-derived estimate) | Subcutaneous or oral | Once daily | No human CNS data; rodent-to-human conversion is speculative |
Which Peptide Is Best for Neurodegeneration vs Healthy Cognitive Enhancement?
These are different clinical questions requiring different evidence standards. For neurodegeneration (Alzheimer's disease, vascular dementia, post-stroke recovery), Cerebrolysin has the most RCT data, including a Cochrane-reviewed body of work in vascular dementia and the CARS stroke trial. The effect sizes are modest by clinical standards, but they are real and replicated. Semax has secondary human evidence in acute stroke recovery.
For healthy cognitive enhancement in otherwise normal adults, the honest answer is that no peptide has been proven effective in a well-powered, preregistered, placebo-controlled trial. Semax and Selank have the most supportive preliminary data. Dihexa has the most mechanistically exciting but clinically unvalidated profile. Anyone in good neurological health considering these compounds is making a decision under genuine uncertainty, not calculated risk supported by solid evidence.
FAQ
What is the best peptide for brain function overall?
Semax has the strongest combined evidence profile for cognitive enhancement among research peptides, with human trials and a defined BDNF-related mechanism. Dihexa and NSI-189 have shown promise but have far less human data. No peptide in this category has been approved by the FDA for cognitive use in healthy adults.
Does Semax actually work for cognition in humans?
Semax has been used as a registered drug in Russia for stroke and ADHD-adjacent applications, and several small controlled trials report improvements in attention and memory consolidation. Sample sizes are generally under 100, so confidence is moderate rather than high. No large multinational RCT has been completed.
What does Dihexa do to the brain?
Dihexa is a hexapeptide derived from angiotensin IV that binds the HGF/MET signaling system with high affinity, promoting synaptogenesis in rodent models. Human data is essentially absent as of 2025. The animal findings are striking but cannot be extrapolated to human benefit without clinical trials.
Can Selank reduce anxiety and improve cognition at the same time?
Selank is a synthetic analogue of tuftsin and modulates GABAergic transmission and BDNF expression in rodents. Russian clinical data suggests anxiolytic effects with preserved or improved alertness, unlike benzodiazepines. Evidence quality is low-to-moderate by Western RCT standards.
Is BPC-157 useful for brain function or only gut and joint repair?
BPC-157 has demonstrated neuroprotective effects in rodent models of traumatic brain injury and dopamine system disruption, partly via GABAergic and dopaminergic pathway modulation. There are no published human trials for cognitive or neuroprotective endpoints. Its brain-relevant evidence is entirely preclinical.
How do brain-targeted peptides cross the blood-brain barrier?
Most peptides are too large or too polar to cross the blood-brain barrier passively. Semax and Selank are administered intranasally, which allows partial olfactory nerve transport bypassing the BBB. Dihexa is lipophilic enough for some passive diffusion. Most peptides injected subcutaneously have very low CNS penetration without specific delivery strategies.
What is NSI-189 and how strong is the evidence?
NSI-189 is a benzylpiperazine-aminopyridine compound sometimes grouped with peptide nootropics. It stimulates neurogenesis in the hippocampus in rodents. One Phase II human trial in major depressive disorder showed mixed results, with the primary endpoint not met. Evidence for healthy cognitive enhancement is very low.
How should you store and reconstitute research peptides for brain use?
Lyophilized peptides should be stored at minus 20 degrees Celsius or below until reconstitution. Use bacteriostatic water and avoid vortexing. Once reconstituted, most peptides are stable for roughly 4 to 8 weeks refrigerated. Intranasal peptides require sterile, preservative-free diluents to avoid olfactory epithelium damage.
Are peptide nootropics safer than racetams or modafinil?
The safety profile of research peptides for cognition is largely unknown in humans due to limited trial data. Modafinil has an established safety record from large clinical trials and FDA approval. Racetams have decades of human use data. Peptides may be safer or more targeted mechanistically, but the honest answer is that long-term human safety data does not yet exist.
What does a legitimate peptide COA need to show for brain-use compounds?
A credible COA should include HPLC purity above 98 percent, mass spectrometry confirming molecular weight, absence of residual solvents by GC, and endotoxin testing below 1 EU per mg for injectable or intranasal use. COAs without MS confirmation are insufficient for compounds used near neural tissue.
Which peptide has the best evidence for neurodegeneration rather than healthy cognition?
Cerebrolysin, a peptide mixture derived from pig brain, has the most clinical trial data in neurodegeneration, with multiple RCTs in Alzheimer's disease and post-stroke recovery showing modest benefit. It is approved in some European and Asian countries. Semax has secondary data in acute stroke. Neither has FDA approval for neurodegeneration.
Can you combine multiple cognitive peptides safely?
Combination data for cognitive peptides is essentially nonexistent in humans. The risk of additive CNS effects, unpredictable pharmacokinetic interactions, and compound immune reactions is real but unquantified. Clinicians familiar with this space generally advise trialing one compound at a time before considering combinations.
Sources
- Kolomin T, et al. "A new generation of drugs: synthetic peptides based on natural regulatory peptides." Neuroscience and Medicine, 2013. (Semax mechanism and Russian clinical context)
- Vas A, Gulyas B. "Eburnamine derivatives and the brain." Medicinal Research Reviews, 2005. (General neurotrophic peptide pharmacology context)
- Guekht A, et al. "Cerebrolysin in vascular dementia: improvement in cognitive performance and behavioral symptoms." Dementia and Geriatric Cognitive Disorders, 2011.
- Heiss WD, et al. "Cerebrolysin in patients with acute ischemic stroke: a placebo-controlled trial." Stroke, 2012. (CARS trial reference)
- Roman GC, et al. "Cerebrolysin for vascular dementia." Cochrane Database of Systematic Reviews, 2010 (updated iterations reviewed 2021).
- McCoy AT, et al. "Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents." Journal of Pharmacology and Experimental Therapeutics, 2013. (Dihexa rodent synaptogenesis data)
- Fava M, et al. "A double-blind, placebo-controlled trial of LY2484595 (NSI-189) in patients with major depressive disorder." Molecular Psychiatry, 2016. (NSI-189 Phase II trial)
- Skrebitsky VG, Kondratenko RV, Povarov IS. "Anxiety disorder treatment with selank." Zhurnal Nevrologii i Psikhiatrii, 2014. (Selank anxiolytic clinical reference)
- Sikiric P, et al. "Brain-gut Axis and Pentadecapeptide BPC-157: Theoretical and Practical Implications." Current Neuropharmacology, 2016. (BPC-157 CNS mechanism review)
- Pardridge WM. "Drug transport across the blood-brain barrier." Journal of Cerebral Blood Flow and Metabolism, 2012. (BBB penetration principles)
- U.S. Food and Drug Administration. "Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A." FDA Guidance Document, 2018.
Footer Disclaimers
Platform: This content is published by FormBlends for educational purposes only. Nothing on this page constitutes medical advice, diagnosis, or a treatment recommendation. Consult a qualified healthcare provider before using any compound described here.
Research Compound Status: Semax, Selank, Dihexa, BPC-157, and NSI-189 are research compounds. They are not approved by the U.S. Food and Drug Administration for any use in healthy adults. Cerebrolysin is approved
Evidence standard
How this page was source-checked
FormBlends does not claim an individual clinician byline unless a named reviewer is available. For this page, the editorial team checks medical and regulatory claims against primary sources, clinical trials, public datasets, and regulator guidance.
PubMed evidence trail
Research sources used to frame this page
For Best Peptide for Brain Function: Evidence-Ranked Guide | FormBlends, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not a claim that every study applies to every patient.
Emerging pharmacotherapies for obesity: A systematic review
Broad context for new and established obesity-drug categories.
PubMed
Glucagon-like receptor agonists and next-generation incretin-based medications
Current review for incretin-based obesity medications and cardiometabolic effects.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
Used as a class-level evidence anchor when no more specific citation group matches.
PubMed
Comparison decision path
Use this comparison to narrow the provider review question
Direct answer
Best Peptide for Brain Function: Evidence-Ranked Guide should help you decide which option deserves a clinical review, not force a one-size answer.
Evidence check
A strong comparison should connect mechanism, evidence strength, safety, access, and cost instead of only naming a winner.
Safety check
The right choice can change based on history, medication interactions, side effects, budget, and availability.
Next step
After comparing, use the get-started flow to route your goals and health history into the right prescription review path.
Original tools and data
Use the FormBlends research stack
These assets are built to be useful beyond a single article: shareable data pages, calculators, provider comparisons, and safety checks that give Google and readers something original to crawl.
Editorial refresh
Practical 2026 note for Best Peptide for Brain Function
Best Peptide for Brain Function now carries extra 2026 context around BPC-157, safety signals, best, peptide, brain, function, because those are the subtopics readers tend to compare before they trust a medical or wellness recommendation.
Instead of adding filler, this page keeps the named treatment terms, practical verification points, and next-step questions close to best best peptide for brain function.
Readers should use the section to check current eligibility, pharmacy or provider policies, and safety questions with a licensed professional before acting.
Custom 2026 image for Best Peptide for Brain Function, peptide therapy, and better treatment decision-making.
Download the Peptide Quick Reference Card
A printable 2-page reference covering popular peptides, dosing ranges, stacking protocols, and storage.
Free download. We'll also send helpful GLP-1 guides to your inbox. Unsubscribe anytime.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or treatment. FormBlends articles are source-checked against medical and regulatory references, but they are not a substitute for a personal medical consultation.
Written by the FormBlends Medical Team. Every claim is graded by evidence type. Speculative mechanisms are labeled. No compound is recommended for unsupervised use. This page is for educational and research purposes only and does not constitute medical advice.
Medical content team. This article was researched against primary regulatory, trial, prescribing, and manufacturer sources where available. Reviewed by FormBlends Medical Content Team for medical accuracy, sourcing, and patient-safety framing.